Vaccine Research in Australia: Landscaping capabilities and relevant services

Banner Image

Internationally, vaccines are one of the fastest growing sectors in the pharmaceutical and biotechnology industry. This project seeks to create a streamlined pathway for Australian vaccine development from the time of conception at the laboratory bench, typically in a University research lab, all the way through to human trials and commercialisation.

Whilst Australia has an exemplary record of basic immunology and vaccine research, there has been a major failure to capture the commercial value of this Australian research. This project will landscape the vaccine space, developing a free-to-use, publicly accessible database of all interested parties in the sector, and draw them together for the first Australian Vaccine conference in December 2017.

Outcomes (FY2020):

  • A better connected Australian vaccine community, engaging through events and in person. 
  • Ten events have been held with over 350 attendees. 
  • Two products have been developed and 5 pre-clinical and one clinical trial have commenced.

Visit Vaxine to learn more.

Listen to Vaxine's Professor Nikolai Petrovsky on the quest for a COVID-19 vaccine 

Twitter: vaxine_news

LinkedIn: Vaxine

Consortium lead Vaxine Pty Ltd
Consortium members Mylexa Pty Ltd, Australian Respiratory and Sleep Medicine Institute Ltd
MTPConnect grant $250,000
Industry contributions $250,000
Project duration March 2017 - May 2018 (Completed)
Contact Sharen Pringle, Vaxine -